The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases
Sude H AKTIMUR,
Umit Y. MALKAN,
Damla N EYUPOGLU,
İbrahim C. HAZNEDAROĞLU,
Engin KELKİTLİ,
Hilmi M ATAY,
Gürsel GÜNEŞ,
Sezgin ETGÜL,
Tuncay ASLAN,
Hakan GÖKER,
NİLGÜN SAYINALP,
SALİH AKSU,
Osman İ. ÖZCEBE,
Yahya BÜYÜKAŞIK,
MEHMET TURGUT